caa a22 4500 445802375 CHVBK 20180317145145.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1007/s10337-010-1818-0 doi (NATIONALLICENCE)springer-10.1007/s10337-010-1818-0 Pharmacokinetic Study of ZS-1, a Targeted Peptide to NCI-H1299, in Rats Following Intravenous Administration [Elektronische Daten] [Junqiang Luo, Xun Li, Xuediao Pan, Jie Zhou, Wenbin Feng, Dalu Liu, Linquan Zang] To investigate the pharmacokinetics of ZS-1 following intravenous injection in rats, ZS-1 was administered at doses of 20, 30 and 45mgkg−1, respectively. Blood samples were collected at 0.5, 3, 8, 12, 15, 20, 30, 40 and 45min. ZS-1 in rat plasma was measured by LC. The limit of detection (LOD) was 0.02μgmL−1. The relative standard deviation (RSD) of intra- and inter-day precisions were <10%, and the accuracy of intra- and inter-day were >94%. The mean extraction recovery of ZS-1 was 86.1%. After intravenous injection at doses of 20, 30 and 45mgkg−1, the concentration-time curves of ZS-1 fitted well to one compartment model. Area under the concentration-time curves (AUC) increased with dose. Clearance rates (CL) and elimination half-lives (T 1/2) had no significant difference between different dose groups (P>0.05). ZS-1 was stable in plasma after at 25°C for 2, 4, 6h, after three freeze-thaw cycles, after −20°C for a month, and after −80°C for 3months. The accuracy of ZS-1 was between 96.8 and 106.9%. The results indicated there was no significant degradation. These data indicated that the method for analysis of ZS-1 was reliable and the pharmacokinetic data could guide dosing regimens to be tested in future clinical pharmacokinetic study. Springer-Verlag, 2011 Column liquid chromatography nationallicence Pharmacokinetics study nationallicence Lung cancer nationallicence Polypeptide nationallicence Luo Junqiang Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Li Xun Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Pan Xuediao Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Zhou Jie Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Feng Wenbin Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Liu Dalu Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Zang Linquan Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut Chromatographia Vieweg Verlag 73/1-2(2011-01-01), 177-181 0009-5893 73:1-2<177 2011 73 10337 https://doi.org/10.1007/s10337-010-1818-0 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10337-010-1818-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Luo Junqiang Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Li Xun Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Pan Xuediao Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Zhou Jie Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Feng Wenbin Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Liu Dalu Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Zang Linquan Department of Pharmacology, Novel Drug Screening Center, Guangdong Pharmaceutical University, 510006, Guangzhou, People's Republic of China aut NATIONALLICENCE 773 0- Chromatographia Vieweg Verlag 73/1-2(2011-01-01), 177-181 0009-5893 73:1-2<177 2011 73 10337 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer